Literature DB >> 26818954

Progress toward a Respiratory Syncytial Virus Vaccine.

Kathleen M Neuzil1.   

Abstract

In accompanying papers (P. L. Acosta, M. T. Caballero, and F. P. Polack, Clin Vaccine Immunol 23:189-195, 2016, http://dx.doi.org/10.1128/CVI.00609-15; M. Vissers, I. M. L. Ahout, M. I. de Jonge, and G. Ferwerda, Clin Vaccine Immunol 23:243-245, 2016, http://dx.doi.org/10.1128/CVI.00590-15) in this issue of Clinical and Vaccine Immunology, the history of and immune mechanisms underlying vaccine-enhanced respiratory syncytial virus (RSV) disease and of investigations of mucosal antibodies and their association with viral load in RSV-infected children, respectively, are described. This commentary discusses RSV vaccine candidates, target populations, and the challenges associated with achieving a safe and effective vaccine.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26818954      PMCID： PMC4783429          DOI： 10.1128/CVI.00037-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  11 in total

1.  Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels.

Authors:  Marloes Vissers; Inge M L Ahout; Marien I de Jonge; Gerben Ferwerda
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

2.  Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.

Authors:  Helen Y Chu; Mark C Steinhoff; Amalia Magaret; Khalequ Zaman; Eliza Roy; Gretchen Langdon; Mary Anne Formica; Edward E Walsh; Janet A Englund
Journal:  J Infect Dis       Date:  2014-06-05       Impact factor: 5.226

Review 3.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

4.  Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.

Authors:  Pedro A Piedra; Alan M Jewell; Stanley G Cron; Robert L Atmar; W Paul Glezen
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

5.  The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.

Authors:  Angelia Eick; Ruth Karron; Jana Shaw; Bhagvanji Thumar; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2008-03       Impact factor: 2.129

6.  A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.

Authors:  Ruth A Karron; Cindy Luongo; Bhagvanji Thumar; Karen M Loehr; Janet A Englund; Peter L Collins; Ursula J Buchholz
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

7.  Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

Authors: 
Journal:  Pediatrics       Date:  2014-08       Impact factor: 7.124

8.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

Authors:  W P Glezen; A Paredes; J E Allison; L H Taber; A L Frank
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

9.  Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.

Authors:  Piero Poletti; Stefano Merler; Marco Ajelli; Piero Manfredi; Patrick K Munywoki; D Nokes; Alessia Melegaro
Journal:  BMC Med       Date:  2015-03-10       Impact factor: 8.775

10.  The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.

Authors:  Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240
View more
  32 in total

1.  Pathogenesis, Humoral Immune Responses, and Transmission between Cohoused Animals in a Ferret Model of Human Respiratory Syncytial Virus Infection.

Authors:  Karen L Laurie; Patrick C Reading; Kok Fei Chan; Louise A Carolan; Julian Druce; Keith Chappell; Daniel Watterson; Paul Young; Daniil Korenkov; Kanta Subbarao; Ian G Barr
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 2.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

3.  Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Trudy G Morrison
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

4.  Why Should We Advocate Maternal Immunization?

Authors:  Jim Boonyaratanakornkit; Helen Y Chu
Journal:  Pediatr Infect Dis J       Date:  2019-06       Impact factor: 2.129

5.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

6.  Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site.

Authors:  Tatiana Kotomina; Daniil Korenkov; Victoria Matyushenko; Polina Prokopenko; Larisa Rudenko; Irina Isakova-Sivak
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

7.  Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.

Authors:  Tatiana Kotomina; Irina Isakova-Sivak; Victoria Matyushenko; Ki-Hye Kim; Youri Lee; Yu-Jin Jung; Sang-Moo Kang; Larisa Rudenko
Journal:  Antiviral Res       Date:  2019-05-07       Impact factor: 5.970

Review 8.  Respiratory syncytial virüs infections in neonates and infants.

Authors:  Yıldız Perk; Mine Özdil
Journal:  Turk Pediatri Ars       Date:  2018-06-01

9.  Determining the Seasonality of Respiratory Syncytial Virus in the United States: The Impact of Increased Molecular Testing.

Authors:  Claire M Midgley; Amber K Haynes; Jason L Baumgardner; Christina Chommanard; Sara W Demas; Mila M Prill; Glen R Abedi; Aaron T Curns; John T Watson; Susan I Gerber
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

Review 10.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.